Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Kura Oncology emerges as a public company via reverse merger, raises $52.5mm through first PIPE

Executive Summary

Kura Oncology Inc. (precision medicines for blood and solid cancers) came out of the gates as a new public company following a reverse merger with defunct public shell entity Zeta Acquisition. Kura concurrently raised $52.5mm through a private placement, and converted $7.5mm in bridge notes to common shares.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies